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Introduction
The clonal evolvement of tumors by sequential mutation caus-
es the genotypic heterogeneity of tumor cells (1). In addition, the 
detection of cancer stem cells demonstrated that tumor cells exhib-
it considerable phenotypic plasticity and heterogeneity (2, 3).
The substantial impact of tumor-associated stromal cells on 
tumor pathogenesis was recognized only recently. Tumor cells inter-
act with stromal cells through soluble factors (for example VEGF, 
PDGF, angiopoietins, or inflammatory cytokines), deposited factors, 
such as extracellular matrix proteins, and also through direct cell-cell 
interactions. This mutual crosstalk is commonly referred to as the 
tumor microenvironment (TME). The TME can activate or restrain 
tumor progression, malignancy, or the occurrence of metastasis (4). 
The heterogeneity of tumor cells may also induce the plasticity and, 
as a consequence, the heterogeneity of the stromal cells. However, 
few studies have yet investigated the phenotypic and genotypic vari-
ability of stromal cells associated with different TMEs.
Stromal cell plasticity and subsequent heterogeneity may 
present a serious problem for stromal cell–directed therapeutic 
approaches. At present, antiangiogenic therapy is the major stro-
mal cell–directed therapy. This approach is based on the concept 
that tumor growth requires angiogenesis (5). Among other rea-
sons, tumor endothelial cells (TECs) were considered druggable 
therapeutic targets because they were regarded as phenotypically 
homogenous and genetically stable in contrast to tumor cells (5). 
In the past decade, tumor vessels and TECs have become targets 
of tumor therapy in colorectal carcinoma (CRC) and numerous 
other human solid tumors, such as renal cell carcinoma, lung car-
cinoma, and glioblastoma (6–9). However, clinical efficacy was 
moderate, and evidence indicates that TECs differ from normal 
endothelial cells (NECs) by gene expression and phenotype (10, 
11). The plasticity and/or heterogeneity of TECs may severely 
impair antiangiogenic therapy approaches. Endothelial cells (ECs) 
originating from different vascular beds are heterogeneous with 
respect to gene expression and cellular structure. Accordingly, 
EC heterogeneity was detected in tumors arising from different 
organs (12). In addition, a recent study in mice has suggested that 
phenotypic heterogeneity of ECs may be induced by different 
TMEs (13). This study showed that murine TECs that were iso-
lated from xenotransplanted tumors induced by the injection of 
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Figure 1. Study groups were established according to isolated TECs from CRC tissues that had an angiostatic Th1-TME or a non-Th1 control-TME as 
well as comparable microvessel densities and senescence. (A) In total, 58 pure TEC cultures were isolated from 117 patients using a CD31-based MACS 
protocol. The isolation success was 49.6%. After application of stringent quality criteria (QC) (see main text), 16 TEC cultures derived from CRC tissues with 
an angiostatic Th1-TME (n = 8, blue) and control-TME (n = 8, pink) were subjected to transcriptome analyses. (B) For the study, all tumors with angiostatic 
Th1-TME (GBP-1hi) and those with a non-Th1 control-TME (GBP-1lo) and less favorable prognosis were differentiated by GBP-1 expression (brown, arrows) 
using IHC. Scale bar: 250 μm. (C) Microvessel density was detected by CD31 staining (left panel) in tumors from B. For each tumor, the average number of 
microvessels per optical field was calculated and is shown (right panel). Scale bar: 50 μm. (D) RT-qPCR of SA β-gal expression in the tumors from B. The 
expression levels are given as 40-Ct values. (C and D) Statistical significance was determined by Student’s t test. Mean values are indicated by line; NS, 
not significant.
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established from the isolated cultures on the basis of numer-
ous different quality criteria, as detailed below, and were then 
compared by transcriptome analysis.
We observed differential GBP-1 expression in the primary 
tumors of the TEC cultures that were ultimately included (Figure 
1B). Both groups were closely matched with respect to the clinical 
characteristics of the patients (e.g., Union for International Can-
cer Control  [UICC] stage, grading, lymph/venous invasion, age, 
and sex) (Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI78260DS1). Moreover, 
different numbers of vessels and/or ECs in the tissues may influ-
ence the isolation procedure and/or the biologic features of the 
established TEC cultures. Therefore, the microvessel density was 
quantified after CD31 staining in consecutive tissue sections of 
the same tumors that were used for cell isolation. Only those TEC 
cultures were included in which the microvessel densities in the 
primary tumors did not yield to significant differences between 
the GBP-1hi or GBP-1lo groups (Figure 1C). Of note, microvessel 
density counts only assess the presence of blood vessels but do not 
indicate the degree of active angiogenesis or the functional status 
of tumor neovascularization (20). In order to rule out the possi-
bility that the tumor tissues exhibit differences in cell age/senes-
cence, the expression of senescence-associated β-gal (SA β-gal) as 
an established marker of cell senescence (21) was determined in 
the original tumor biopsies. Again, only those TEC cultures were 
included in which senescence in the originating GBP-1hi or GBP-1lo 
CRC tissues was not different (Figure 1D).
In previous studies, the cross-contamination of TECs with, for 
example, pericytes was reported as an issue when using the cells 
directly after the first isolation approach (11, 22). In order to avoid 
this problem, we used an isolation protocol with repeated cycles 
of purification and cultivation of cells (10). In a first approach, 
the enrichment and purity of TECs were determined after each 
magnetic activated cell sorting (MACS ) cycle by CD31 immuno-
cytochemistry (Supplemental Figure 1A). Purification cycles were 
repeated until microscopic evaluation showed that all of the cells 
were positive for CD31 (Figure 2A and all TEC cultures shown in 
Supplemental Figure 1B). Of note, cytochemical CD31 staining 
was detected using the permanent alkaline phosphatase–anti- 
alkaline phosphatase (APAAP) system instead of the more com-
mon fluorescence-based detection method, as the permanent 
system showed increased sensitivity particularly for subconflu-
ent EC cultures (Supplemental Figure 2). HUVECs, monocytes 
(THP-1), and T cells (Jurkat) were used as positive controls, and 
CRC cells (DLD-1), primary smooth muscle cells (SMCs), and 
fibroblasts were used as negative controls (Figure 2A). In a second 
approach, we established a specific marker panel (CD31, vWF, 
CD105, VE-cadherin, CK-20, CD45, and desmin) that allowed us 
to determine the purity of isolated TECs by reverse transcription 
quantitative PCR (RT-qPCR) analysis. The TEC expression pattern 
was identical to the one obtained with HUVECs (CD31pos, vWF-
pos, CD105pos, VE-cadherinpos, CK-20neg, CD45neg, and desminneg) 
and clearly different from TEC expression patterns of other con-
trol cell types (Figure 2B and Supplemental Table 2). Sensitivity 
analyses using RT-qPCR demonstrated that cross-contamina-
tion with DLD-1, SMC, fibroblasts, monocytes, or T cells can be 
detected within a range of 0.1% to 2%, depending on the cell type 
low and highly metastatic melanoma cells exhibit a differential 
expression of VEGFR1 and VEGFR2, VEGF, HIF-1α, or CD90 (13). 
It is unknown whether TECs within a human solid tumor entity 
may acquire different phenotypes according to the specific TME.
TMEs are strongly affected by the immune response. Differ-
ent immune responses in CRC are associated with different clini-
cal outcomes. A positive outcome with increased survival is asso-
ciated with a Th1 response that is activated in a subgroup of the 
patients (14, 15). This response is associated with increased T cell 
density and robust IFN-γ activation (15). It has been shown that 
the IFN-γ–induced GTPase guanylate-binding protein 1 (GBP-1) is 
a sensitive marker for Th1 responses in CRC (ref. 14 and reviewed 
in ref. 16). This process is also characterized by a strong immuno-
angiostatic response caused by the increased expression of IFN-γ–
induced angiostatic chemokines such as CXCL-9, CXCL-10 (also 
known as IP-10), CXCL-11 and the angiostatic functions of GBP-1, 
which is expressed in ECs (14, 17, 18). GBP-1 expression in CRC 
is an independent prognostic factor. High expression levels of 
GBP-1 (hereafter referred to as GBP-1hi) are associated with a 
Th1-TME, reduced angiogenic activity, lower tumor aggressive-
ness, and improved cancer-related survival of the patients. In 
contrast, low expression levels of GBP-1 (hereafter referred to as 
GBP-1lo) are characterized by the absence of a Th1-like reaction, 
increased angiogenic activity, increased tumor aggressiveness, 
and reduced cancer-related survival (14). These findings were 
recently confirmed by a comprehensive marker study by The Can-
cer Genome Atlas (TCGA) Consortium, which also reported that 
GBP-1 is a robust marker for reduced aggressiveness in CRC (19). 
Accordingly, in this study, we differentially categorized the TMEs 
according to GBP-1 expression as angiostatic Th1-TME (GBP-1hi) 
or angiogenic non-Th1 control-TME (GBP-1lo).
The aim of this study was to investigate the impact on TEC 
plasticity and heterogeneity of 2 TMEs that are associated 
with different prognoses of patients with CRC. This approach 
was based on the hypothesis that isolated TECs in culture may 
stably maintain TME-induced changes in their transcriptomes 
due to TME-dependent imprinting processes. The proof of 
concept was addressed by the analysis of whether differential-
ly expressed genes can be confirmed in the tumor tissues and 
whether they may functionally contribute to the manifestation 
of the respective TME.
Results
Pure tumor ECs can be isolated from CRCs with different prog-
nostic TMEs. In order to analyze the TME-induced plasticity 
and heterogeneity of TECs in human CRC, ECs were isolat-
ed from 2 groups of primary tumors that had different TMEs 
associated with different prognoses. The overall course of the 
study group selection is summarized in Figure 1A. Altogether, 
tumors from all available patients in a time period of 3 years 
(n = 117) were included. Pure TECs were obtained in 58 cas-
es (isolation success: 49.6%). Tumors with different prognos-
tic TMEs were discriminated by GBP-1 expression. GBP-1 is 
detected in roughly 30% of CRCs (14) and thus required the 
processing of a higher number of tumors until a sufficiently 
large-sized group was obtained. Two different groups of TECs 
from the angiostatic Th1-TME and non-Th1 control-TME were 
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transcriptomes showed highly significant differences in the path-
way analysis, this biological phenotype has not yet been deposit-
ed in the databank and thus has to be regarded as unknown.
Single gene analysis of the microarray results using sig-
nificance analysis of microarray (SAM) revealed in the TECs 
of the GBP-1hi group 205 upregulated and 97 downregulated 
genes (FDR <20%, ≥2-fold change). The top 50 upregulated 
and downregulated genes are depicted in a heatmap (Figure 3B; 
blue: antitumorigenic genes are indicated by arrows, and anti-
angiogenic genes are indicated by arrowheads; pink: tumori-
genic genes are indicated by arrows, and angiogenic genes are 
indicated by arrowheads) and are presented in full detail in Sup-
plemental Table 6. Numerous genes with antitumorigenic activ-
ity (e.g., SPARCL1 [ref. 24], ADAMTS9 [ref. 25]), DYRK1A [ref. 
26], and CAMK2N1 [ref. 27]) and antiangiogenic activity (e.g., 
SEPT9 [ref. 28], ADAMTS9 [ref. 29], and PTPN23, also known 
as HD-PTP [ref. 30]), were upregulated in GBP-1hi TECs char-
acterized by a Th1-TME. Among the most strongly downregu-
lated genes, tumorigenic genes such as LAMC2 (31), leupaxin 
(32), or ADAM12 (33), and angiogenic genes, such as SERPIND1 
(34), HEY2 (35), or EDIL3 (36) were detected. Accordingly, gene 
expression in the TECs within the GBP-1hi group reflected the 
intertumoral activity (angiostatic and antitumorigenic) associ-
ated with the Th1-TME in CRC. Interestingly, GBP-1 itself was 
that was used for spiking (Supplemental Table 3). This result indi-
cated that the purity of the isolated TECs was greater than 98%. 
To exclude the possibility that the isolation procedure may have 
induced differences, we assured that the numbers of purifica-
tion and cultivation cycles (Figure 2C) and the expression of 
the senescence marker SA β-gal (Figure 2D) were not different 
between the 2 groups. After implementing these stringent qual-
ity control approaches, 2 groups of highly pure TEC cultures (n 
= 8 each) were ultimately established from CRCs with different 
prognostic TMEs.
Differential gene expression of cultivated TECs reflects the bio-
logic activity and clinical prognosis associated with the intertumoral 
TME. The transcriptomes of the TECs that were derived from the 
GBP-1hi (n = 8) and GBP-1lo (n = 8) groups were determined. Gene 
set enrichment analysis (GSEA) revealed highly significant dif-
ferences between TECs from both groups as depicted by a heat-
map (Figure 3A) and the corresponding detailed list of the top 
features for each gene set (Supplemental Table 4). Among all of 
the GSEA major collections, the most valid significantly enriched 
gene set (FDR <25%) associated with GBP-1hi TECs was HOXA9_
DN.V1_DN (Supplemental Figure 3 and Supplemental Table 5). 
HOXA9_DN.V1_DN is a knockout gene set of the proangiogenic 
transcription factor HOXA9 (23), which is in agreement with the 
angiostatic activity of the GBP-1hi–associated TME. Although the 
Figure 2. TECs isolated from CRC with an 
angiostatic Th1-TME and control-TME are 
pure and show an EC phenotype. (A) The 
purity of TEC cultures was determined 
by CD31 immunocytochemical staining. 
CD31-positive control cells (pink, arrows) 
were primary ECs (HUVECs), monocytes 
(THP-1), and T cells (Jurkat); CD31-negative 
control cells were CRC cells (DLD-1), primary 
SMCs, and primary fibroblasts. Scale bar: 
100 μm. (B) Expression of a panel of cell 
type–specific markers was analyzed in 
isolated TECs after CD31 staining (see A) 
and indicated high purity compared with 
control cells. All TECs showed expression of 
markers (purple boxes) identical to that of 
HUVECs (orange frame). CK-20, CD45, and 
desmin were continuously negative (white 
boxes), excluding contamination with CRC 
tumor cells, SMCs, fibroblasts, monocytes, 
and T cells. Detailed values are provided in 
Supplemental Table 2. (C) Dot plot shows 
the number of MACS cycles required to 
obtain pure TEC cultures. (D) Expression 
of SA β-gal was determined by RT-qPCR 
in the isolated TEC cultures. Expression 
levels are indicated as 40-ΔCt values. SA 
β-gal expression could not be determined 
in 3 TEC cultures due to consumption of 
the respective RNAs by transcriptome 
and purity analyses. (C and D) Statistical 
significance was determined by Student’s t 
test. Mean values are indicated by line; NS, 
not significant.
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SPARCL1 is an EC-associated protein that is highly expressive 
in normal colon and progressively lost in more aggressive CRC. In a 
next step, we validated in detail whether the gene expression of 
isolated TEC cultures may reflect the biological features associ-
ated with a specific TME. Secreted protein, acidic and rich in cys-
not differentially expressed between TECs that were isolated 
from GBP-1hi and GBP-1lo tumors. In conclusion, the intertumor-
al TME may exert specific cellular imprinting effects on TECs, 
as reflected by the expression of a specific cluster of indicator 
genes in isolated cultures of these cells.
Figure 3. Pure TECs isolated from CRC with an angiostatic Th1-TME and control-TME maintain differential transcriptomes in culture. (A) RNA was isolat-
ed from TECs derived from GBP-1hi and GBP-1lo CRC (see Figure 2) and analyzed by hybridization to HG-U133-Plus 2.0 gene chips (Affymetrix). Heatmap of 
the top 50 features for each phenotype (GBP-1hi versus GBP-1lo) as identified by GSEA. A detailed list of the identified features is provided in Supplemental 
Table 4 and the enriched gene sets in Supplemental Table 5. (B) Heatmap of the differentially regulated genes as identified by SAM. The top 50 up- and 
downregulated target genes regulated by more than 2-fold are depicted. A detailed list of the genes is provided in Supplemental Table 6. Gene functions 
according to the literature. Blue: antitumorigenic = arrows, antiangiogenic = arrowheads; pink: tumorigenic = arrows, angiogenic = arrowheads. 
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teine–like 1 (SPARCL1) was the most strongly upregulated gene 
in TECs isolated from GBP-1hi CRCs (Supplemental Table 6) and 
was therefore used as a model for subsequent experiments.
SPARCL1 is a secreted matricellular glycoprotein belonging 
to the SPARC family, with SPARC/osteonectin as its closest family 
member (37). SPARCL1 is described as an antiadhesive protein (38) 
that exerts antitumorigenic activity specifically in CRC if recom-
binantly expressed in or added as a purified protein to RKO or 
Figure 4. SPARCL1 is an EC-associated protein that is highly expressed in normal colon and progressively lost in more aggressive CRCs. (A) SPARCL1 
expression (pink, arrows) was determined by IHC in normal colon and CRC tissues. Tumor cells are labeled with asterisks. Isotype antibody staining of 
consecutive sections was used as a negative control. Scale bar: 50 μm. (B) Colocalization of SPARCL1, α-SMA, and CD31 was determined by immunoflu-
orescence triple staining (SPARCL1, green; α-SMA, blue; CD31, red). A triple staining with the respective isotype antibodies is depicted as a control. All 
tissues were counterstained using DAPI (white), but this is depicted only for the isotype staining. Inserts are representative higher-magnification images 
of the 296 vessels counted, showing colocalizations of SPARCL1 and CD31 (arrows) and SPARCL1 and α-SMA (arrowheads) (n = 10 normal colon, n = 20 
CRCs). Scale bar: 25 μm; original magnification, ×4.3 (inserts). (C) SPARCL1 expression was quantified by RT-qPCR in normal colon and corresponding 
CRC tissues (n = 42). 40-ΔCt values are shown at the individual patient level and in a box and whisker plot (insert). ***P < 0.001, by Student’s t test. Line 
corresponds to mean value. (D) SPARCL1 and CD31 expression was detected after immunofluorescence staining in normal colon, GBP-1hi CRC, and GBP-1lo 
CRC (n = 9 each). The relative content of SPARCL1-positive ECs per vessel was categorized and determined for 10 vessels per patient (n = 270 total vessels). 
The relative number of vessels with different SPARCL1 expression (%) is indicated by different gray tones. ***P < 0.001, by χ2 test. (E) SPARCL1 and GBP1 
expression was quantified in CRC tissues  (n = 127) by RT-qPCR. Expression is indicated in 40-ΔCt values. Pearson’s correlation (r = Pearson’s correlation 
coefficient) was performed in order to determine statistical significance. Line corresponds to linear regression.
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SW620 cell lines (24, 37). As yet in CRC tissues, SPARCL1 expres-
sion has been detected in CRC tissues, but conflicting results exist 
with respect to its presence in tumor cells and/or ECs, and, as 
such, its association with prognosis is a subject of controversy (24, 
39). As yet, nothing is known about the regulation or induction of 
SPARCL1 expression or its functional impact on vessel phenotype 
in human carcinomas.
Given these uncertainties, we first attempted to clarify which 
cell types were expressing SPARCL1 in human CRC and normal 
colon tissues (for the clinical characteristics of all patients ana-
lyzed by IHC here and below, see Supplemental Table 7). The 
expression results were validated by 3 independent methods 
(permanent staining, immunofluorescence, and ISH). Using this 
approach, specific SPARCL1 signals were preferentially observed 
in ECs and less frequent in mural cells, in both the normal colon 
and CRC tissues at the protein (Figure 4, A and B) and RNA (Sup-
plemental Figure 4) levels. Of note, CRC tumor cells were nega-
tive (Figure 4A, asterisks). EC-associated expression was con-
firmed by costaining with CD31 (Figure 4B, arrows) and mural 
cell–associated expression using α–smooth muscle actin (α-SMA) 
costaining (Figure 4B, arrowheads). Quantitative evaluation of 
the staining results from 296 vessels in the normal colon and CRC 
tissues showed that SPARCL1 was exclusively expressed in ECs in 
the majority of cases (69.3% of the vessels); 23% of the vessels had 
SPARCL1 expression in both ECs and mural cells; and only in rare 
cases (7.8% of the vessels) was SPARCL1 expression exclusively 
observed in mural cells (Figure 4B). Triple-isotype control stain-
ing was negative (Figure 4B).
The quantitative analysis of SPARCL1 expression by RT-qPCR 
in the normal colon and the respective tumor tissues of the same 
patients (n = 42, for clinical characteristics see Supplemental Table 
8) revealed that SPARCL1 expression was significantly downreg-
ulated in the tumors (Figure 4C). Analyses of vessel-associated 
SPARCL1 expression at the single-cell level using immunohisto-
chemical double staining of SPARCL1 and CD31 mostly revealed 
a mosaic-like expression pattern of SPARCL1 staining that was 
not detected in every EC of the tumor vessels (Figure 4B). The 
quantitative evaluation of SPARCL1 signals in vessels of GBP-1hi 
and GBP-1lo tumors compared with those present in normal 
colon tissues showed that vessels without SPARCL1 expression 
were much more commonly observed in GBP-1lo CRC than in 
GBP-1hi CRC or normal colon tissues (Figure 4D, black area). In 
contrast, the association of SPARCL1 expression with GBP-1hi 
CRC was validated in an independent cohort of 127 CRC patients 
(for clinical patients’ characteristics, see Supplemental Table 8). 
A highly significant correlation between GBP1 and SPARCL1 
Figure 5. SPARCL1 expression is induced by EC confluency and is further increased by Th1-associated cytokines. Different cultures of HUVECs and 
MVECs were seeded with 30,000 cells/cm² and were grown for the indicated time periods. SPARCL1 expression was determined by (A) immunofluores-
cence staining (SPARCL1, green; DAPI, blue) (scale bar: 100 μm), (B) Western blot analysis (β-tubulin was used as a loading control), and (C) RT-qPCR 
(expression indicated as 40-ΔCt values). Error bars indicate SD. (D) MVECs expressing SPARCL1 after 5 days of confluence were treated with the recom-
binant human cytokines IFN-γ (100 U/ml), IL-2 (100 ng/ml), and IL-4 (20 ng/ml) for 24 hours in complete medium (n = 3). Subconfluent cells were used as 
a control. Protein extracts were analyzed by SPARCL1/GAPDH Western blotting, and signals were quantified by a digital chemiluminescence imager. The 
normalized signal intensities (SPARCL1/GAPDH) are indicated below the Western blot.
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as SPARCL1 expression was reduced upon treatment with the 
Th2-associated cytokine IL-4 (Figure 5D; see complete unedited 
blots in the supplemental material.). SPARCL1 expression was not 
affected by any of the other factors (data not shown). This indicat-
ed that TME-associated cytokines may contribute to differential 
expression of SPARCL1.
SPARCL1 is a marker of EC quiescence. Cell quiescence is 
defined as a reversible, resting state induced by cell conflu-
ence. At the molecular level, quiescence is characterized by low 
or absent expression of the proliferation marker Ki-67 and high 
expression of the quiescence marker nuclear IL-33 (47, 48). In 
order to investigate whether SPARCL1 is associated with cell 
quiescence, the expression of SPARCL1, Ki-67, and nuclear 
IL-33 was analyzed in subconfluent and confluent HUVECs 
and MVECs. Subconfluent cultures were highly positive for 
Ki-67 and negative for nuclear IL-33 and SPARCL1, whereas 
confluent cultures were highly positive for nuclear IL-33 and 
SPARCL1 and showed reduced proliferation, as indicated by the 
few Ki-67–positive cells (Figure 6A). Moreover, proliferation of 
SPARCL1-positive ECs was also significantly reduced compared 
with that of SPARCL1-negative ECs after transient ectopic over-
expression of SPARCL1 in subconfluent cells (SPARCL1-posi-
tive ECs, 8.1% vs. SPARCL1-negative ECs, 21.8%) (Figure 6B). 
Analysis of heterogeneously dense EC cultures revealed con-
fluence-induced SPARCL1 expression that was associated with 
nuclear IL-33 expression and reduced Ki-67 expression in areas 
with high cell density, whereas in other areas, SPARCL1 expres-
sion and nuclear IL-33 levels were low or absent and cell pro-
liferation was high (Figure 6C). Of note, cell proliferation was 
also reduced and nuclear IL-33 expression increased in SPAR-
CL1-negative cells in close vicinity to the SPARCL1-positive 
cells, indicating limited paracrine effects of SPARCL1 (Figure 
6C). Moreover, confluence-induced SPARCL1 expression was 
reversible after the experimental removal of the confluent state 
by scratching the cell layer (Figure 6D). Cells migrating into the 
scratched area did not show SPARCL1 expression at 14 hours 
(Figure 6D, arrowheads) and reexpressed SPARCL1 after 48 
hours when reaching confluence again (Figure 6D). Moreover, 
in a long-term time course experiment, ECs were grown from 
the subconfluent SPARCL1-negative, proliferating, nonquies-
cent state (Figure 6E, day 1) to the confluent state after 15 days 
and 22 days (Figure 6E, days 15 and 22). The confluent state 
resulted in an increase of expression of SPARCL1 and nuclear 
expression was detected by RT-qPCR and confirmed the associ-
ation of increased SPARCL1 expression with a Th1-TME in CRC 
tissues (Figure 4E).
SPARCL1 expression is induced by EC confluency and further 
increased by Th1-associated cytokines. Isolated TECs from GBP-1hi 
CRC expressed SPARCL1, whereas other studies did not detect 
SPARCL1 expression in ECs in culture, including HUVECs and 
human microvascular ECs (MVECs) (11). Moreover, the regulation/
induction of SPARCL1 expression is unclear at present. First, we 
investigated whether SPARCL1 expression in TECs from GBP-1hi 
CRC may be increased due to induction by TME-associated growth 
factors or cytokines. To this end, we treated HUVECs and MVECs 
synchronized by starvation at approximately 70% confluence with 
15 different recombinant proteins including IFN-γ, IFN-α, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-17, IL-1β, TNF-α, TGF-β1, CXCL-10, 
VEGF, basic FGF (bFGF), and EGF. The concentrations used have 
been shown to be active on ECs in studies by our group (IFN-γ, 
IL-4, IL-6, IL-10, IL-1β, TNF-α, CXCL-10, VEGF, and bFGF [ref. 
40]; IFN-α [ref. 41]) and by others (IL-2 [ref. 42]; IL-8 [ref. 43]; 
IL-17 [ref. 44]; TGF-β1 [ref. 45]; and EGF [ref. 46]). In no instance 
was SPARCL1 expression detected at the protein level (data not 
shown). Interestingly, SPARCL1 expression in CRC tissues was 
highest in quiescent ECs from normal colon tissues and in GBP-1hi 
CRCs, which exhibit endogenous angiostatic activity. This sug-
gested that SPARCL1 expression in ECs may be induced by cell 
quiescence. In agreement with this hypothesis, we found that 
SPARCL1 expression was induced in ECs upon reaching conflu-
ence (Figure 5A). This finding was confirmed in different types of 
ECs (HUVECs, MVECs) as well as in single-donor HUVECs and 
HUVEC pools from different donors (Figure 5A). In contrast, none 
of these EC cultures expressed SPARCL1 in a subconfluent, prolif-
erative state (Figure 5A, day 0). In total, 9 of 14 different EC cul-
tures expressed SPARCL1 after cells reached the confluent state. 
Confluence-induced SPARCL1 expression in ECs was confirmed 
at the protein level by Western blot analysis (Figure 5B; see com-
plete unedited blots in the supplemental material.) and at the RNA 
level using RT-qPCR (Figure 5C). In order to investigate wheth-
er TME-associated cytokines may affect confluence-associated 
SPARCL1 expression, ECs were kept confluent for 5 days to induce 
endogenous SPARCL1 expression and were then incubated with 
the same cytokines as those mentioned above. Under these condi-
tions, the treatment with the Th1-associated cytokines IFN-γ and 
IL-2 resulted in a further increase of SPARCL1 expression, where-
Figure 6. SPARCL1 is a marker of EC quiescence. (A) MVECs were plated on chamber slides and grown to subconfluent and confluent states. Cells were 
costained by IHC for SPARCL1/Ki-67 or SPARCL1/IL-33 (SPARCL1, green; Ki-67/nuclear IL-33, pink, arrowheads; DAPI, blue). Scale bar: 75 μm. Graph depicts 
the relative numbers (percentages) of Ki-67– and nuclear IL-33–positive cells per optical field. Error bars indicate SD. (B) HUVECs were transiently trans-
fected with a human SPARCL1 expression plasmid. Cells were incubated 24 hours after transfection for 2 hours with 10 μM EdU. Afterward, the Click-iT 
reaction was performed according to the manufacturer’s protocol, and SPARCL1 was stained (EdU, pink; SPARCL1, green; DAPI, blue). Scale bar: 50 μm.  
The relative amount of EdU-positive cells was determined in both SPARCL1-positive and SPARCL1-negative cells (n = 1,883). Error bars indicate SD. (C) 
HUVECs were plated on chamber slides and grown until confluence was reached in some areas. The cells were immunocytochemically stained for SPARCL1/
Ki-67 or SPARCL1/IL-33, and confocal images of areas with inhomogenous confluence were acquired (SPARCL1, green; Ki-67/nuclear IL-33, pink, arrow-
heads; DAPI, blue). Scale bar: 100 μm. (D) Confluent cell layers of MVECs were scratched and immunocytochemically stained for SPARCL1 after 0, 14, and 
48 hours (SPARCL1, green, DAPI, blue). The migration front is marked by a dashed white line, and cells migrating into the scratch that had lost SPARCL1 
expression are labeled with arrowheads. Scale bar: 250 μm. (E) HUVECs were grown in parallel dishes for 1, 15, or 22 days. On day 15, cells from 1 dish were 
reseeded at a low density (subcultivated - at day 15) and grown for an additional 8 days (subcultivated - at day 22). The slides were immunofluorescently 
costained for SPARCL1/Ki-67 and SPARCL1/IL-33 expression (SPARCL1, green; Ki-67/nuclear IL-33, pink, arrowheads; DAPI, blue). Scale bar: 100 μm.  
(A and B) ***P < 0.001, by Student’s t test . (A, B, and D) One representative experiment of two independent experiments is depicted.
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SPARCL1 is associated with mature vessels. Quiescence is 
commonly observed in mature vessels. Therefore, we analyzed 
the association of SPARCL1 expression with vessel maturation 
in the normal colon as well as in GBP-1hi and GBP-1lo CRC tis-
sues. Sprouting, angiogenically active vessels exhibit reduced 
vessel perimeter, vessel area, and mural cell coverage compared 
with mature quiescent vessels (49, 50). Accordingly, the rela-
tionship between SPARCL1 expression and these parameters 
was quantified. The vessels were categorized into SPARCL1hi 
(>50% SPARCL1-positive ECs/vessel) and SPARCL1lo (<50%) 
IL-33 that was associated with reduced proliferation (reduced 
Ki-67 staining, Figure 6E, days 15 and 22). After activation of 
the cells by subcultivation, both cultures rapidly lost SPARCL1 
expression, which was paralleled by increased Ki-67 expression 
and loss of nuclear IL-33, showing evasion from cellular quies-
cence (Figure 6E, subcultivated days 15 and 22). In summary, 
these results showed that SPARCL1 expression is induced in 
quiescent ECs and reversibly downregulated in proliferating 
and migrating ECs, which are both characteristically associated 
with the angiogenic activation of ECs.
Figure 7. SPARCL1 expression is 
associated with mature vessels. (A) 
Expression of SPARCL1 (green) and CD31 
(red) was detected by immunofluores-
cence costaining in normal colon, and 
GBP-1hi and GBP-1lo CRC (n = 9 each). The 
combined isotype antibodies were used 
for the control staining. Tissues were 
counterstained with DRAQ5 (Cell Sig-
naling Technology; blue). Colocalization 
is indicated by arrows. CD31 expression 
only is indicated by an arrowhead. Scale 
bar: 25 μm. Vessel perimeters and areas 
were quantitatively determined for all 
the stained vessels (n = 270; 10 vessels/
patient) and are depicted as dot plots 
(red bars indicate the mean values and 
SD). (B) The vessel perimeters and areas 
as quantified in A in relation to vessels 
with high and low SPARCL1 expression 
for all tissues. (C) Immunofluorescence 
costaining of SPARCL1 (green), CD31 
(red), and α-SMA (blue). Scale bar: 25 μm. 
α-SMA–positive mural cell coverage was 
categorized as negative/weak, moderate, 
or high for 296 vessels from 30 patients, 
and the relative size of each category 
is given for SPARCL1hi and SPARCL1lo 
vessels. The relative amount of coverage 
is depicted for vessels with SPARCL1 
expression in ECs only (n = 205). The 
relative number of vessels with different 
alpha-SMA coverage (%) is indicated by 
different gray tones. (A and B) Repre-
sentative experiment of 2 independent 
experiments is depicted. *P < 0.05 and 
***P < 0.001, by ANOVA, with Levene and 
Games-Howell (unequal variance) tests 
(A), Student’s t test (B), and χ2 test (C).
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ic activity of adjacent SPARCL1-negative tumor vessels at the 
paracrine level and, by doing so, may functionally contribute to 
the angiostatic effect of a Th1-like TME.
In a final step, we investigated whether SPARCL1 released 
from quiescent ECs may contribute to the induction or mainte-
nance of vessel maturation. Human SMCs were used as a mural 
cell model in vitro. Purified recombinant SPARCL1 (1.5 μg/ml) sig-
nificantly inhibited PDGF-induced (PDGF-AA and PDGF-BB, 10 
ng/ml each) migration, as confirmed by 2 different tests (Figure 
9A, scratch and transmigration assays). In contrast, SPARCL1 did 
not inhibit PDGF-induced proliferation of SMCs under these con-
ditions (Figure 9A). These results indicated that SPARCL does not 
directly activate vessel maturation but instead blocks the activity 
of mural cells and thereby may stabilize mature vessels, thus sup-
porting homeostasis. In agreement with this, we detected signifi-
cantly reduced mural cell coverage in colon vessels of mice with 
homozygous knockdown of SC1 (the mouse homolog of SPARCL1, 
Sc1–/–, n = 10) (51) as compared with WT C57BL/6 mice (n = 11) 
(Figure 9B). In addition, colon vessels in Sc1–/– mice were signifi-
cantly smaller as determined by measuring vessel perimeters and 
areas (Figure 9B). Altogether, the results obtained in the mouse 
model were in striking agreement with those obtained in human 
colon tissues. All of our results congruently support the idea that 
SPARCL1 is an EC-derived factor that contributes to the manifes-
tation of the prognostically favorable Th1-TME in GBP-1hi CRC.
Discussion
We found that TECs from CRC tissues with varying degrees of 
aggressiveness stably maintain differences in gene expression 
during in vitro cultivation. We identified SPARCL1 as a highly 
expressed protein in TECs from CRC with a favorable prognosis 
and low or absent expression in TECs of aggressive CRC. Func-
tional analyses showed that SPARCL1 is a novel regulator of EC 
quiescence that, through additional paracrine functions, stabiliz-
es mature vessels and contributes to the favorable prognosis asso-
ciated with a Th1-TME (for graphical summary see Figure 10).
The TME-dependent heterogeneity and plasticity of TECs 
may result in the moderate response rates associated with anti-
angiogenic cancer treatment regimens (6–8, 9). EC heterogene-
ity has been noticed among different organs, in different seg-
ments of the vascular tree, and across different diseases (12). 
Mouse studies provided the first evidence that TECs may exhibit 
TME-dependent heterogeneity (13, 52). So far, to our knowledge, 
no such studies have been reported for human solid tumors.
Recent research activities, including the Discovery Thera-
peutic Program of the National Cancer Institute, strengthen the 
role of cultivated cells as useful models of tumor heterogeneity 
(53). On the basis of these studies, we investigated the hetero-
geneity of TECs from CRC with different TMEs using freshly 
isolated TECs as a model system. The in vitro culture of prima-
ry cells may result in culture-induced alterations. Therefore, we 
carefully matched the 2 groups to be compared in terms of clin-
ical parameters (see Supplemental Table 1), vessel content, and 
senescence of the tissues as well as the number of MACS puri-
fications, age/senescence, and high purity of the cells (>98%). 
This resulted in  the inclusion of 16 of 58 cultures isolated from 
117 patients in the transcriptome analyses. In order to keep the 
vessel groups (patients’ characteristics are listed in Supplemen-
tal Table 7). Costainings for SPARCL1/CD31 expression (Figure 
7A) and morphometric analyses of vessel structure showed that 
vessel perimeters and areas were similar in the normal colon 
and GBP-1hi CRC tissues but significantly decreased in GBP-1lo 
CRC tissues. Moreover, in all 3 tissues, SPARCL1hi vessels com-
pared with SPARCL1lo vessels had significantly increased ves-
sel perimeters and areas (Figure 7B). In order to determine the 
mural cell coverage of vessels in relation to SPARCL1 expres-
sion, costaining of CD31, SPARCL1, and α-SMA was performed 
in GBP-1hi and GBP-1lo CRC (Figure 7C; n = 7 each). Quantita-
tive analyses demonstrated that high mural cell coverage was 
detected in 56.5% of SPARCL1hi vessels in GBP-1hi CRC tissues 
but only in 15.5% of the SPARCL1lo vessels in GBP-1lo CRC (Fig-
ure 7C; P < 0.001). α-SMA coverage was only evaluated in those 
vessels that expressed SPARCL1 exclusively in the ECs. Of 
note, vessels with high mural cell coverage were generally sig-
nificantly larger in size (Supplemental Figure 5). These results 
demonstrated that high SPARCL1 expression levels are associ-
ated with mature vessels in normal colon and CRC tissues.
SPARCL1 regulates the homeostasis of mature vessels. SPARCL1 
was associated with mature vessels in an angiostatic Th1-TME. 
Accordingly, we investigated whether SPARCL1 may function-
ally contribute to the inhibition of angiogenesis and vessel mat-
uration. In a first step, we investigated the impact of SPARCL1 
on vessel morphogenesis using the 3D spheroid assay. To this 
end, SPARCL1 was stably overexpressed by retroviral transduc-
tion of ECs using a pBABE-SPARCL1 plasmid in comparison 
with the corresponding empty vector (pBABE). Western blotting 
demonstrated SPARCL1 expression in stably pBABE-SPARCL1–
transduced cells (Figure 8A, left; see complete unedited blots 
in the supplemental material.), and immunocytochemistry con-
firmed that nearly all of the cells expressed SPARCL1 (Supple-
mental Figure 6A). In agreement with the transient transfection 
experimental findings (compare Figure 6B), the proliferation of 
pBABE-SPARCL1–transduced cells was significantly reduced 
compared with that of pBABE-transduced cells (Supplemental 
Figure 6B). In the 3D spheroid assay, sprout formation of SPAR-
CL1-expressing cells was significantly reduced compared with 
that observed in pBABE-transduced cells (Figure 8A, middle and 
right). In contrast, the transient knockdown of endogenously 
expressed SPARCL1 with a specific siRNA (Figure 8B, left) result-
ed in a significant enhancement of 3D-sprouting as compared 
with cells transfected with a control-siRNA (Figure 8B, middle 
and right). These findings confirmed that SPARCL1 expression 
exerts antiangiogenic activity in ECs and inhibits vessel morpho-
genesis. SPARCL1 can be secreted from cells (38) and therefore 
may also exert paracrine functions. Using a specific SPARCL1 
ELISA, we detected increasing concentrations of SPARCL1 in 
the cell culture supernatants of different batches of confluent 
HUVECs and MVECs after 5 days of confluence (Supplemental 
Figure 7A). In our investigation of the effects of secreted SPAR-
CL1, we found that purified recombinant human SPARCL1 sig-
nificantly inhibited the proliferation (Figure 8C), migration (Fig-
ure 8D and Supplemental Figure 7B), and 3D sprouting (Figure 
8E) of ECs in a concentration-dependent manner. Accordingly, 
SPARCL1 released from quiescent ECs can inhibit the angiogen-
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with an angiostatic Th1-TME and was low or absent in more 
aggressive, angiogenically active CRC tissues. This led to the 
hypothesis that SPARCL1 expression may be associated with 
quiescent vessels. This consideration was further supported by 
reports on the absence of SPARCL1 expression in cultivated cells 
based on in vitro analyses of proliferating subconfluent cultures 
(11, 57). Cellular quiescence is defined as a nonproliferating, 
resting state of confluent cells that is reversible after a prolifer-
ative stimulus. The nuclear localization of IL-33 is a marker of 
EC quiescence and is rapidly lost upon an angiogenic stimulus 
(59). SPARCL1 expression in primary ECs was induced when 
the cells reached the confluent nonproliferating state associated 
with the expression of nuclear IL-33 and was fully reversible after 
the cells were subjected to nonconfluent conditions. The differ-
ential expression of SPARCL1 in CRC may be due to the mainte-
nance of TEC quiescence in a Th1-TME by IFN-γ and additional 
angiostatic genes (CXCL9, CXCL10, CXCL11, and GBP1) that are 
induced by this cytokine and, conversely, to the downregulation 
of SPARCL1 expression in the angiogenic TME of aggressive 
CRC (14, 60). This hypothesis was supported by our observa-
tion that Th1-associated cytokines like IFN-γ and IL-2 increased 
SPARCL1 expression, whereas the Th2-associated cytokine IL-4 
slightly reduced SPARCL1 expression. Of note, these effects 
were exclusively observed in confluent conditions with already 
detectable SPARCL1 expression but not in proliferating subcon-
fluent cultures of ECs. This indicated that the TME-associated 
cytokines have modulatory functions but are not sufficient for a 
complete shut-off or de novo induction of SPARCL1 expression.
Cultivated TECs were expanded, and it may be asked why 
differential SPARCL1 expression was maintained in proliferating 
cells. In this framework, it must be considered that, in order to 
maintain a maximal yield, we isolated the RNA for transcriptome 
analyses from TECs that were confluent for 48 hours. Therefore, 
differential SPARCL1 expression in cultivated TECs may be due 
either to the more rapid induction of SPARCL1 in confluent cul-
tures of TECs from a Th1-TME, or to the impaired expression of 
SPARCL1 in TECs that were derived from aggressive CRC tis-
sues. With this in mind, we investigated how stable the observed 
changes in gene expression were and whether longer conflu-
ence durations may have influenced the results. To this end, the 
expression of 2 upregulated genes (SPARCL1, ADAMTS9) and 
2 downregulated genes (HEY2, EDIL3) after 2, 4, and 6 days of 
cultivation time as short as possible, the selected TEC cultures 
were directly and in total subjected to RNA isolation as soon as 
sufficiently high cell numbers were reached.
Several of the genes that were upregulated in TECs from GBP-1hi 
CRC were antiangiogenic or antitumorigenic. For example, antian-
giogenic genes included septin 9 (SEPT9) and protein tyrosine phos-
phatase, nonreceptor type 23 (PTPN23), which inhibit EC prolifera-
tion and migration, respectively (28, 30). The antitumorigenic genes 
included ADAMTS9, which blocks tumor growth by inhibition of Akt 
activation (25); DYRK1A, which inhibits the growth of AML cells (26), 
and CAMK2N1, which inhibits prostate cancer progression through 
androgen receptor–dependent signaling (27). These activities were in 
line with the originating tumors, suggesting that TECs derived from 
CRC with a Th1-TME express a set of “memory genes.” Of note, no 
significant overlap was observed with the “memory genes” detected 
in previously reported studies in mouse models (13, 52).
In our study, the expression of several genes with antitum-
origenic activity suggested that TECs may actively contribute to 
a less aggressive course of the disease in a Th1-TME. In order 
to validate this hypothesis, we focused on SPARCL1, which was 
the most strongly upregulated gene in Th1-TME–derived TECs. 
SPARCL1 is a member of the SPARC family of secreted matricel-
lular proteins, together with SPARC/osteonectin, SMOCs, testi-
cans, and follistatin-like protein 1 (37). SPARCL1 was shown to 
be a tumor suppressor in various cancers such as CRC (24), pan-
creatic cancer (54), and prostate cancer (55). SPARCL1 inhibits 
EC adhesion and spreading (38), but its direct impact on EC pro-
liferation, migration, and capillary morphogenesis has not been 
investigated. Moreover, nothing is known about the regulation/
induction of SPARCL1 expression. Its closest family member, 
SPARC/osteonectin, can inhibit angiogenesis (56). Here, we 
found that SPARCL1 expression in CRC tissues was highly asso-
ciated with ECs and positively correlated with the Th1-mark-
er molecule GBP-1 (reviewed in ref. 16). The almost exclusive 
expression of SPARCL1 in ECs was the subject of controversy 
in previous studies (24, 39). However, our results are strongly 
supported by the consistent confirmation we obtained with 3 
different methods (permanent IHC, immunofluorescence IHC, 
and ISH) and the agreement with studies by others in humans 
and mouse models (11, 57, 58).
Interestingly, SPARCL1 expression was typically high in 
angiogenically inactive ECs from normal colon and CRC tissues 
Figure 8. SPARCL1 is an antiangiogenic protein. (A) HUVECs were stably transduced by a retroviral SPARCL1-encoding vector (pBABE-SPARCL1) and 
the corresponding control vector (pBABE). Increased SPARCL1 expression in these cells was confirmed by Western blotting and immunocytochemistry 
(Supplemental Figure 6A). In agreement with earlier results, the cells showed significant inhibition of angiogenic growth factor–induced (AGF-induced) 
proliferation by SPARCL1 (AGF = combined bFGF/VEGF, 10 ng/ml each; positive control) (Supplemental Figure 6B). SPARCL1 overexpression significantly 
reduced bFGF-induced 3D sprouts from spheroids embedded in collagen/methocel matrices. (B) MVECs were transiently transfected with an siRNA (50 
nM) specifically targeting SPARCL1 and with a control siRNA. Reduction of SPARCL1 RNA expression in cells transfected with the SPARCL1 siRNA was 
confirmed by RT-qPCR. In parallel, the same cells were used for spheroid formation, and 3D sprouting was assessed after 24 hours. (C) HUVECs were either 
untreated (mock) or treated with AGF (positive control), AGF and IFN-γ (100 U/ml, negative control), or AGF with increasing concentrations of recombinant 
SPARCL1. Cell numbers after 6 days are shown. (D) HUVECs were plated on Transwell inserts (8 μm) and treated as in C for 6 hours. Migrated cells at the 
lower membrane side were determined by counterstaining with DAPI (Supplemental Figure 7B), and the mean values of cells counted per optical field are 
shown. (E) Spheroids from HUVECs were embedded in a collagen/methocel gel and stimulated as described in C, except that bFGF was used alone instead 
of AGF for 24 hours in duplicate experiments. The sprout lengths of 20 spheroids per stimulation were quantitatively determined and are indicated as the 
mean cumulative sprout length per spheroid. All experiments were performed 3 times in triplicate, except the spheroid assays, which were performed in 
duplicate, with 10 spheroids quantified per group. *P < 0.05 and ***P < 0.001, by Student’s t test (A and B) or ANOVA, with Levene and Bonferroni’s (equal 
variance) or Games-Howell (unequal variance) test (C–E). (A, B, and E) Scale bars: 250 μm. (A–E) Error bars indicate SD.
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induced SPARCL1 expression supports a role for TME-associated 
cytokines (see above). Moreover, pH, nutrient content, oxygen 
delivery, hypoxia, ROS, blood flow, and mechanical forces might 
induce TME-associated variations in TECs (61). TME-based 
imprinting effects in TECs may be based on epigenetic modifica-
tions, which are commonly associated with environmental and/
or genetic alterations that have been described in TECs from 
experimental mouse models (63) and human renal cell carcino-
mas (64) or other nongenetically manifested but inherited pro-
cesses that have recently been described in tumor cells (65).
confluence was analyzed in 3 EC cultures with either high or low 
endogenous SPARCL1 expression on day 2 of confluence (har-
vest time point transcriptome analysis). In all cases, the differ-
ential gene expression pattern was always present during the 6 
days, demonstrating that stable differential gene expression pat-
terns are maintained in these EC cultures (Supplemental Figure 
8). TME-associated differences in TECs may be caused by dif-
ferent soluble factors, extracellular matrix components, or to the 
recruitment of endothelial progenitor cells (EPCs) (12, 61, 62). 
The modulatory effect of IFN-γ, IL-2, and IL-4 on confluence- 
Figure 9. SPARCL1 regulates vessel maturation. (A) Primary human SMCs were treated with recombinant human SPARCL1 (1.5 μg/ml) and migration 
(scratch and transmigration assays) as well as proliferation were analyzed. Human recombinant PDGF (PDGF-AA and PDGF-BB, 10 ng/ml each) was used 
as a positive control to activate SMC migration and proliferation. Human recombinant IFN-γ (100 U/ml) served as a negative control. PDGF-induced closure 
of the wound was significantly inhibited by SPARCL1 (left); PDGF-induced transmigration was significantly inhibited by SPARCL1 (middle); and PDGF- 
induced proliferation of SMCs was not inhibited by SPARCL1 (right). Representative experiments of 2 (right and left) and 3 (middle) independent experi-
ments are depicted. Lines indicate SD. (B) Colon tissue of WT (n = 11) and Sc1–/– mice (n = 10) was immunostained for SC1 (green), CD31 (red), and α-SMA 
(blue). Vessels are indicated by arrows. α-SMA–positive mural cell coverage was categorized as negative/weak, moderate, or high for 210 vessels, and the 
relative number of vessels for each category is shown for WT and Sc1–/– vessels (left). Vessel perimeters and areas (n = 210) were quantitatively determined 
and are depicted by dot plots (red bars represent the mean values and SD). Scale bar: 25 μm. *P < 0.05 and ***P < 0.001, by ANOVA, with Levene and 
Bonferroni’s (equal variance) or Games-Howell (unequal variance) test (A), χ2 test B, bar graph), or Student’s t test (B, dot plots).
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(EGM-2-MV; Lonza); MVECs (EGM-2-MV; Lonza), SMCs (Medium 
231 and SMGs; both from Thermo Fisher Scientific); NHDFs (DMEM-
10% FBS; Thermo Fisher Scientific); THP-1 (RPMI-10% FBS; Thermo 
Fisher Scientific); Jurkat (RPMI-10% FBS); and DLD-1 (RPMI-10% 
FBS). All of the cells were cultivated according to the manufacturer’s 
instructions and were routinely tested for mycoplasma negativity 
using the MycoAlert Mycoplasma Detection Kit (Lonza). The cell lines 
were regularly authenticated by DNA–short tandem repeat (DNA-
STR) genotyping (DSMZ).
Cells were stimulated with human recombinant proteins in the 
following concentrations, if not otherwise indicated: bFGF (10 ng/
ml; Roche); IFN-γ (100 U/ml; Roche); IL-2 (100 ng/ml; PromoKine); 
IL-4 (20 ng/ml; R&D Systems); PDGF-AA (10 ng/ml; R&D Systems); 
PDGF-BB (10 ng/ml; R&D Systems); SPARCL1 (1.5 μg/ml; R&D Sys-
tems); and VEGF165 (10 ng/ml; R&D Systems).
Isolation of TECs from CRC and quality control parameters
Isolation of TECs was performed according to our previously pub-
lished detailed protocols (10, 67). All patients had CRC without 
pretreatment. The study group was selected after the individuals 
passed several quality parameters, which included matching clini-
cal characteristics of the patients, similar microvessel density, and 
senescence in originating tissues; a similar number of MACS cycles 
for cell isolation; similar senescence of isolated cells; an EC purity 
of more than 98%; mycoplasma negativity of all cultures; an RNA 
yield of 10 μg or greater; RNA integrity as determined by the Expe-
rion RNA StdSens Analysis Kit (Bio-Rad); and an RNA concentra-
tion of 1 μg/ml or greater.
Transient transfection of ECs
SPARCL1 overexpression. HUVECs were seeded in 1.5% gela-
tin-coated, 4-well chamber slides (BD Biosciences) with 2 × 104 
cells per well 24 hours before transfection. A mixture of 0.6 μg 
SPARCL1 cDNA (NM_004684.5, position 471-2465) inserted into 
the pMCV1.4(+) (Mologen AG) expression vector; 30 μl Opti-MEM 
(Life Technologies, Thermo Fisher Scientific); and 6 μl SuperFect 
Transfection Reagent (QIAGEN) was incubated at room temperature 
for 10 minutes and then together with 164 μl EGM2-MV medium add-
Interestingly, gain- and loss-of-function experiments demon-
strated that SPARCL1 blocks blood capillary morphogenesis. 
In addition, recombinant SPARCL1 inhibited the proliferation, 
migration, and sprouting of ECs. These results indicated that 
SPARCL1 contributes functionally to EC quiescence and proba-
bly to angiostasis in CRC with a Th1-TME. Moreover, at the tissue 
level in CRC, SPARCL1 was markedly associated with parameters 
of vessel maturation, such as increased mural cell coverage and 
increased vessel areas and perimeters. In agreement with the 
latter finding, a mouse model with a defective Sc1 gene (mouse 
homolog of SPARCL1) also had fewer mature vessels. Within 
this framework, it is interesting that the closest family member, 
SPARC/osteonectin, is known to foster pericyte/mural cell recruit-
ment (66). Given these results, we investigated whether SPARCL1 
may induce and/or maintain vessel maturation. We found that 
recombinant SPARCL1, in contrast to SPARC/osteonectin, does 
not act as a chemoattractant for SMCs but inhibits the migration 
of these cells. This indicated that SPARCL1 may predominantly 
preserve mature vessels but probably does not induce maturation.
Altogether, we demonstrated that SPARCL1 contributes func-
tionally to EC quiescence and blood vessel homeostasis. Specifically 
in CRC, the quiescence-inducing activity of SPARCL1 may contribute 
to the angiostatic micromilieu associated with a Th1-TME. In addi-
tion, SPARCL1 is secreted, and inhibitory effects on different tumor 
cell lines have been reported (24, 54, 55). Accordingly, SPARCL1 may 
be among the first EC-derived proteins with antitumorigenic activity, 
contributing to the positive prognosis associated with a Th1-TME.
Methods
Cell culture
HUVEC pools were purchased either from PromoCell or Cambrex. 
Primary human SMCs and primary normal human dermal fibroblasts 
(NHDFs) were purchased from Promocell, MVECs were purchased 
from Lonza, and THP-1, Jurkat, and DLD-1 from the DSMZ (Braunsch-
weig, Germany). Single-donor HUVECs were provided by B. Dietel. 
The cells were kept in the following media: HUVECs (endothelial cell 
growth medium) from PromoCell or B. Dietel; HUVECs from Lonza 
Figure 10. Role of SPARCL1 in CRC. SPARCL1 is expressed in ECs of 
tumor vessels in CRC with an angiostatic Th1-TME (green). SPAR-
CL1-positive vessels show increased mural cell coverage (left, blue) 
and increased vessel area and perimeter (left). Detection of nuclear 
IL-33 (orange) and low or absent proliferation indicates quiescence 
of SPARCL1-positive ECs. SPARCL1 expression is low in CRC tissues 
lacking an angiostatic Th1-TME (right). SPARCL1-negative vessels 
exhibit increased proliferation rates (Ki-67, red) and smaller vessel 
areas and perimeters (right). SPARCL1 regulates the Th1-associat-
ed phenotype of TECs. It is secreted from ECs and can inhibit EC 
proliferation and migration in an autocrine (1) or paracrine (2) man-
ner. Moreover, SPARCL1 stabilizes mature vessels by inhibiting the 
activation of mural cells (3). EC-secreted SPARCL1 may also exert 
inhibitory effects on epithelial tumor cells in CRC (4). Differential 
SPARCL1 expression in vivo is maintained in in vitro cultures of 
TECs from CRC tissues with different TMEs.
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changed, and conditioned media were harvested after 24 hours by cen-
trifugation at 1,000 ×g for 10 minutes at 4°C. The extracellular SPARCL1 
amounts in these conditioned media were determined in triplicates.
Supplemental Methods
Isolation of RNA from cell cultures and human colon/CRC tissues, 
RT-qPCR, proliferation, migration, 3D sprouting assays, immunocy-
tochemistry, IHC, and ISH (70, 71) were performed as indicated in the 
Supplemental Methods.
Statistics
Affymetrix expression array. Raw data derived from GeneChips were 
analyzed using the Affymetrix MAS5.0 algorithm and normalized by 
“global scaling” as recommended by Affymetrix. SAM was performed 
on the basis of the signals derived from the MAS5.0 signal summariza-
tion algorithm. SAM analyses based on MAS5.0 signals were restricted 
to probe sets showing 50% or more present detection calls in at least 
1 class. Finally, differentially regulated genes were identified accord-
ing to an FDR (Q value) below 20% and a greater than 2-fold change 
between GBP-1hi and GBP-1lo groups. A heatmap was generated for the 
top 100 differentially regulated genes using Spotfire software (TIBCO 
Software Inc.) and median-normalized log2-transformed signal values. 
GSEA (http://www.broadinstitute.org/gsea/index.jsp) was performed 
for all gene set collections (c1-c7) using MSigDB, version 4.0, as recom-
mend by the Broad Institute.
Correlation RT-qPCR. Statistics for a correlation between SPAR-
CL1 and GBP1 expression in CRCs was performed by Pearson’s cor-
relation test using GraphPad Prism, version 6 (GraphPad Software).
All other analyses. Statistical differences were calculated by 
2-tailed Student’s t test, χ2 test, or ANOVA followed by post-hoc anal-
ysis using SPSS, version 21 (IBM), as indicated in the figure legends. A 
P value of less than 0.05 was considered significant.
Study approval
Patients. All patients whose tissues were used for TEC isolation had 
CRC and had not received previous preoperative radiation or chemo-
therapy. All procedures were approved by the local ethics committee 
(no. 3402; Ethikkommission der FAU, Erlangen, Germany). Informed 
consent was obtained from all patients before their participation in 
this study. Detailed descriptions of all patient cohorts are provided in 
Supplemental Tables 1, 7, and 8.
Mice. WT and Sc1–/– tissue blocks with normal colons were produced 
in house. (51), and all experiments were performed according to UK 
Home Office guidelines and were approved by the  Animals in Science 
Regulation Unit, Home Office, London, United Kingdom.
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